Medtronic Announces CareGuidePro, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey
Medtronic plc the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. The patient’s care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient’s experience with spinal cord stimulation. …
– Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. The patient’s care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient’s experience with spinal cord stimulatio
Medtronic Announces CareGuidePro™, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey
New App Developed in Partnership with Higgs Boson Health, a Physician-Led Digital Health and Patient Engagement Solutions Provider
News provided by
Share this article
Share this article
DUBLIN, May 5, 2021 /PRNewswire/ Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. The patient s care team, including physicians and Medtronic, may also use the CareGuidePro platform to help manage and support the patient s experience with spinal cord stimulation. Patients also have the ability to record their pain relief and other feedback directly into the app, providing detailed Patient Reported Outcomes (PROs) to ensure timely, essential information is recorded
Medtronic Receives Approval for U.S. Labeling of the Intellis Platform Showing Superior Back Pain Relief When Using DTM Spinal Cord Stimulation
Medtronic plc the global leader in medical technology, today announced the U.S. Food and Drug Administration has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed programming for the treatment of chronic, intractable back and leg pain. The new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with …
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed (DTM™) programming for the treatment of chronic, intractable back and leg pain. The new labeling will include study outcomes from a multicenter randomized control trial reflecting superior ba
Medtronic Receives Approval for U S Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.